Skip to content

Factors that increase the risk of flare ups in Chronic Obstructive Pulmonary Disease Patients

Predictors of Severe Exacerbation in Chronic Obstructive Pulmonary Disease Patients - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/01/079833
Enrollment
102
Registered
2025-01-31
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J441- Chronic obstructive pulmonary disease with (acute) exacerbation

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Centre for Physiotherapy and Rehabilitation Sciences, Jamia Millia Islamia
Lead Sponsor
Metro Centre for Respiratory Diseases
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Age is 40 years to 80 years. Sex is Males and Females. Participants had a clinical diagnosis of COPD confirmed by spirometry value FEV1/FVC less than 0.70 and a grade II, III, or IV airflow limitation according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The grades of the COPD classified as moderate GOLD Stage II where FEV1 greater than or equal to 50% predicted but less than 80% predicted, severe GOLD Stage III where FEV1 is greater than or equal to 30% predicted but less than 50% predicted, very severe GOLD Stage IV where FEV1 is less than 30% predicted. Patients who are hospitalised for severe exacerbation of COPD experience worsening symptoms for a duration of less than 2 weeks.

Exclusion criteria

Exclusion criteria: Patients with additional active inflammatory diseases such as Rheumatoid Arthritis, Systemic Lupus Erythematous, Fibromyalgia, and Inflammatory Bowel Syndrome. The patient presented with Myopathy. Patients with other obstructive pulmonary diseases such as Asthma, Asthma-COPD Overlap Syndrome (ACOS). Patient who had Unstable Angina and Acute Myocardial Infraction.

Design outcomes

Primary

MeasureTime frame
Respiratory Muscle StrengthTimepoint: At Baseline

Secondary

MeasureTime frame
Six-Minute Walk Tests (6-MWT) Pulmonary Function Tests (PFT) Arterial Blood Gas Analysis (ABG)Timepoint: At Baseline

Countries

India

Contacts

Public ContactMahima mayee Tripathy

Jamia Millia Islamia

aqsamuj786@gmail.com8130676908

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026